NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Leerink Partnrs dropped their Q3 2025 earnings estimates for NeuroPace in a research report issued on Wednesday, May 28th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of ($0.22) for the quarter, down from their previous estimate of ($0.21). The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.29) EPS.
A number of other equities research analysts also recently weighed in on the stock. HC Wainwright began coverage on shares of NeuroPace in a research note on Wednesday. They set a "buy" rating and a $18.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research note on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.50.
Check Out Our Latest Report on NPCE
NeuroPace Stock Performance
Shares of NeuroPace stock traded down $0.13 during midday trading on Friday, hitting $12.98. The company had a trading volume of 285,244 shares, compared to its average volume of 160,151. The business's 50 day simple moving average is $12.83 and its two-hundred day simple moving average is $12.18. The stock has a market cap of $425.73 million, a PE ratio of -12.98 and a beta of 2.04. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.98.
NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. The business had revenue of $22.52 million for the quarter, compared to the consensus estimate of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.
Insiders Place Their Bets
In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the sale, the insider now owns 3,238,199 shares of the company's stock, valued at approximately $51,325,454.15. This represents a 4.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 22.20% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in NeuroPace during the 4th quarter worth $29,000. GAMMA Investing LLC bought a new position in shares of NeuroPace in the first quarter worth $53,000. Wells Fargo & Company MN increased its position in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after purchasing an additional 2,279 shares during the period. JPMorgan Chase & Co. increased its position in shares of NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock worth $84,000 after purchasing an additional 6,181 shares during the period. Finally, MetLife Investment Management LLC bought a new position in shares of NeuroPace in the fourth quarter worth $103,000. Institutional investors own 78.83% of the company's stock.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Stories
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
